Publications by authors named "H SEELIGER"
Purpose: In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled, open-label, multicenter phase III trial (EudraCT 2006-006088-22; ClinicalTrials.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the use of near-infrared (NIR) fluorescent labels, specifically indocyanine green (ICG), to detect liver metastases in pancreatic cancer using an athymic mouse model.
- After inducing pancreatic cancer in mice, researchers injected ICG and performed fluorescence imaging, but none of the liver metastases showed detectable ICG uptake.
- The findings indicate that ICG-staining is ineffective for visualizing hepatic metastases associated with pancreatic tumors in this model, prompting the need for further research to understand this limitation.
Article Synopsis
- Interleukin-6 is crucial for the advancement and poor outcomes of pancreatic ductal adenocarcinoma (PDAC), and the study investigates the effectiveness of targeting its signaling with inhibitors like SC144 and raloxifene in combination with paclitaxel.
- In vitro results showed that the combination of paclitaxel and raloxifene significantly inhibited cell growth and increased apoptosis in pancreatic cancer cell lines, while the SC144 combination did not show similar results.
- In an orthotopic mouse model of PDAC, both drug combinations reduced tumor weight and volume, and raloxifene's combination with paclitaxel led to lower survivin expression, indicating a potential pathway for improving chemotherapy outcomes and reducing side effects.
Purpose: Interleukin 6 (IL-6), Oncostatin M (OSM), and downstream effector STAT3 are pro-tumorigenic agents in pancreatic ductal adenocarcinoma (PDAC). Glycoprotein 130 (gp130) is a compound of the IL-6 and OSM receptor complex that triggers STAT3 signaling. SC144 is a small molecule gp130 inhibitor with anticancer activity.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the clinical effects of BRAF mutations in colorectal liver metastases (CRLMs), focusing on their implications for patient survival and treatment outcomes.
- It included 240 patients and found that BRAF V600E mutation correlated with significantly shorter overall survival, while microsatellite stable tumors had shorter recurrence-free survival compared to MSI-high tumors.
- The research concluded that while surgery might be ineffective for patients with extrahepatic disease, resection of neurotic disease (those that couldn't be surgically removed at first) showed promising survival rates when there was no extrahepatic spread.